Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: 10.1158/1078-0432.CCR-22-1587
- Ereignis
-
Veröffentlichung
- (wo)
-
Aachen
- (wer)
-
Universitätsbibliothek der RWTH Aachen
- (wann)
-
2023
- Urheber
-
Graeser, Monika
Gluz, Oleg
Biehl, Claudia
Ulbrich-Gebauer, Daniel
Christgen, Matthias
Palatty, Jenci
Kuemmel, Sherko
Grischke, Eva-Maria
Augustin, Doris
Braun, Michael
Potenberg, Jochem
Wuerstlein, Rachel
Krauss, Katja
Schumacher, Claudia
Forstbauer, Helmut
Reimer, Toralf
Stefek, Andrea
Fischer, Hans Holger
Pelz, Enrico
Zu Eulenburg, Christine
Kates, Ronald
Ni, Hua
Kolberg-Liedtke, Cornelia
Feuerhake, Friedrich
Kreipe, Hans Heinrich
Nitz, Ulrike
Harbeck, Nadia
- Beteiligte Personen und Organisationen
-
WSG-ADAPT investigators
- DOI
-
10.18154/RWTH-CONV-250791
- URN
-
urn:nbn:de:101:1-2023022501243246800049
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:47 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Graeser, Monika
- Gluz, Oleg
- Biehl, Claudia
- Ulbrich-Gebauer, Daniel
- Christgen, Matthias
- Palatty, Jenci
- Kuemmel, Sherko
- Grischke, Eva-Maria
- Augustin, Doris
- Braun, Michael
- Potenberg, Jochem
- Wuerstlein, Rachel
- Krauss, Katja
- Schumacher, Claudia
- Forstbauer, Helmut
- Reimer, Toralf
- Stefek, Andrea
- Fischer, Hans Holger
- Pelz, Enrico
- Zu Eulenburg, Christine
- Kates, Ronald
- Ni, Hua
- Kolberg-Liedtke, Cornelia
- Feuerhake, Friedrich
- Kreipe, Hans Heinrich
- Nitz, Ulrike
- Harbeck, Nadia
- WSG-ADAPT investigators
- Universitätsbibliothek der RWTH Aachen
Entstanden
- 2023
Ähnliche Objekte (12)
Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT HER2+/HR− trial
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial
West WSG WSG
WSG
*WSG*
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
-WSG- | Rh-Ma
Wassersportclub WSG Goldscheuer
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer : a substudy of the neoadjuvant GeparQuinto trial [[Elektronische Ressource]]
Adapt or Die?
Early modulation of circulating MicroRNAs levels in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy
Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT HER2+/HR− trial
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial
West WSG WSG
WSG
*WSG*
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
-WSG- | Rh-Ma
Wassersportclub WSG Goldscheuer
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer : a substudy of the neoadjuvant GeparQuinto trial [[Elektronische Ressource]]
Adapt or Die?
Early modulation of circulating MicroRNAs levels in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy
Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT HER2+/HR− trial
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial
West WSG WSG
WSG
*WSG*
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
-WSG- | Rh-Ma
Wassersportclub WSG Goldscheuer
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer : a substudy of the neoadjuvant GeparQuinto trial [[Elektronische Ressource]]
Adapt or Die?